Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.4723
-0.0057-1.19%
Post-market: 0.47690.0046+0.97%16:34 EDT
Volume:3.90M
Turnover:1.83M
Market Cap:131.30M
PE:-0.95
High:0.4799
Open:0.4792
Low:0.4600
Close:0.4780
52wk High:1.97
52wk Low:0.4600
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.79
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:4.20
PE(LYR):-1.83

Loading ...

Humacyte Price Target Announced at $0.50/Share by Barclays

Dow Jones
·
Yesterday

Humacyte initiated with an Equal Weight at Barclays

TIPRANKS
·
Yesterday

Humacyte Files Form 3 Initial Beneficial Ownership Statement for Director Scott D. Coward

Reuters
·
Sep 29

Humacyte announces addition of Coward, Kuznik to board

TIPRANKS
·
Sep 28

Humacyte Adds Scott Coward to Board, Names Him to Audit Committee

Reuters
·
Sep 28

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

THOMSON REUTERS
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

TIPRANKS
·
Sep 22

Humacyte Says FDA Authorizes Symvess Shelf Life Extension to 36 Months

Reuters
·
Sep 09

Humacyte - to File Supplemental Bla in Nov 2026 for Dialysis Access Indication

THOMSON REUTERS
·
Sep 09

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

THOMSON REUTERS
·
Sep 09

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live
·
Aug 24

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Reuters
·
Aug 24

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS
·
Aug 24

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS
·
Aug 24

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS
·
Aug 24

Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions

THOMSON REUTERS
·
Aug 24

Humacyte Director Keith Anthony Jones Reports Purchase of 10,000 Common Shares Worth $6,930

Reuters
·
Aug 22

Humacyte Director Keith Anthony Jones Acquires 30,000 Shares Worth $17,820

Reuters
·
Aug 20

Humacyte Says Phase 3 V007 Trial Results Show ATEV Tops Fistula for Hemodialysis Access at One Year

Reuters
·
Aug 19

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

THOMSON REUTERS
·
Aug 19